Ascelia Pharma
Biotech – Should I stay or should I go?
The biotech companies are having difficulties in terms of stock prices, initially driven by rising interest rates and energy prices, and in terms of the
3. March 2022
The biotech companies are having difficulties in terms of stock prices, initially driven by rising interest rates and energy prices, and in terms of the
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.